In this model, used GLP-1 receptor agonist (Dulaglutide), a FDA-approved drug for type II diabetes as well as a prospective drug candidate for NAFLD or NASH [47, 48]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.